{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":21,"n_cols":5,"rows_kept":21,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[15,2,15,3],[16,2,16,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910420948603321"]
[null,null,"Titolo",null,"Drug Delivery Challenges and Novel Therapeutic Approaches for Retinal Diseases [[electronic resource] /] / edited by Christopher L. Cioffi"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020"]
[null,null,"ISBN",null,"3-030-56619-6"]
[null,null,"Edizione",null,"[1st ed. 2020.]"]
[null,null,"Descrizione fisica",null,"1 online resource (IX, 272 p. 1 illus.)"]
[null,null,"Collana",null,"Topics in Medicinal Chemistry, , 1862-247X ; ; 35"]
[null,null,"Disciplina",null,"615.19"]
[null,null,"Soggetti",null,"Medicinal chemistry"]
[{"$nulls":4},"Ophthalmology"]
[{"$nulls":4},"Pharmaceutical chemistry"]
[{"$nulls":4},"Medical genetics"]
[{"$nulls":4},"Medicinal Chemistry"]
[{"$nulls":4},"Pharmaceutics"]
[{"$nulls":4},"Clinical Genetics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"An Overview of Retinal Diseases and Current Ocular Drug Discovery -- Ocular Pharmacokinetics and Drug Delivery Challenges -- Models of Pathologies Associated with Age-related Macular Degeneration and Their Utilities in Drug Discovery -- Recent Developments in Agents for the Treatment of Age-Related Macular Degeneration and Stargardt Disease -- Targets and Strategies toward the Development of Therapeutics for Diabetic Retinopathy and Diabetic Macular Edema -- Recent Developments for the Treatment of Glaucoma -- Emerging Gene Therapy Treatments for Retinal Degenerative Diseases. ."]
[null,null,null,"Sommario/riassunto","This book reviews the current state of ocular drug therapy and future therapeutic opportunities for a wide variety of conditions, including Age-related Macular Degeneration, Diabetic Retinopathy and Macular Edema, Glaucoma, and Inherited Retinal Diseases. Retinal diseases are major contributors to moderate or severe vision impairment in adults aged 50 years and older. The respective patient populations for many of these indications is expected to significantly increase as the world population continues to grow older. An improved understanding of the etiological underpinnings of ocular degenerative diseases over the past decade has significantly bolstered ophthalmic drug discovery. In this "]
[{"$nulls":4},"volume, contributions from leading experts explore the unique challenges faced for ocular drug discovery and delivery providing the reader with detailed information on ocular pharmacokinetics, in vitro, ex vivo and in vivo models for retinal disease pathology and emerging gene therapy treatments. The book is intended for all researchers and clinicians who wish to increase their knowledge on the latest findings in ocular drug therapy."]